Critical Outcome Technologies Inc. achieves milestones moving COTI-2 closer to IND filing

London, Ontario (September 11, 2012): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that it has finalized an oral formulation for COTI-2 in moving forward to the final preclinical studies supporting the investigational new drug (IND) submission enabling a Phase 1 clinical trial. This oral formulation is designed to optimize the absorption of an orally administered…

Critical Outcome Technologies Inc. and Western University sign commercial collaboration agreement

London, Ontario (September 6, 2012): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that Western University (Western) has engaged COTI in a commercial collaboration to discover and advance potential therapies designed to minimize Central Nervous System (CNS) scarring following trauma or stroke. Under this engagement COTI will utilize its proprietary technology CHEMSAS® to discover and optimize novel…

Critical Outcome Technologies Inc initiates development and validation of bioanalytical method for COTI-2 Phase 1 Study

Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that it has engaged Algorithme Pharma Inc. (Algorithme) of Montreal, Canada, an internationally recognized contract research organization, to develop and validate the final quantitative method to be used for preclinical and Phase 1 studies for COTI-2. “The development and validation of a bioanalytical method for COTI-2 in human…